BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

21 articles for MG Johnson

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme.EBI
Amgen
Solving time-dependent CYP3A4 inhibition for a series of indole-phenylacetic acid dual antagonists of the PGD(2) receptors CRTH2 and DP.EBI
Amgen
Discovery and in vivo evaluation of dual PI3Kß/d inhibitors.EBI
Amgen
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.EBI
Ligand Pharmaceuticals
Optimization of phenylacetic acid derivatives for balanced CRTH2 and DP dual antagonists.EBI
Amgen
Discovery of AMG 853, a CRTH2 and DP Dual Antagonist.EBI
TBA
Discovery of amide replacements that improve activity and metabolic stability of a bis-amide smoothened antagonist hit.EBI
Amgen
Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel pyridopyridazines.EBI
Amgen
Design of 1-piperazinyl-4-arylphthalazines as potent Smoothened antagonists.EBI
Amgen
Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists.EBI
Amgen
MALT1 MODULATORS AND USES THEREOFBDB
Rheos Medicines
Cycloalkyl-diamines for the treatment of inflammationBDB
Medisynergics
Pyrazole derivatives as MALT1 inhibitorsBDB
Janssen Pharmaceutica
Bicyclic heterocyclic compoundBDB
Mitsubishi Tanabe Pharma
Substituted pyrazoloazepin-8-ones and their use as phosphodiesterase inhibitorsBDB
Leo Pharma
Compounds and their use for reducing uric acid levelsBDB
Acquist
Sulfur-containing compounds targeting vesicular acetylcholine transporterBDB
Washington University
3-amino-pyridines as GPBAR1 agonistsBDB
Hoffmann-La Roche
HSPC-sparing treatments for RB-positive abnormal cellular proliferationBDB
Gi Therapeutics
Discovery of a Highly Selective STK16 Kinase Inhibitor.BDB
Chinese Academy of Sciences
Inhibition of arginine aminopeptidase by bestatin and arphamenine analogues. Evidence for a new mode of binding to aminopeptidases.BDB
University of Wisconsin